Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A β2-agonist as a CFTR activator in cystic fibrosis – Part 2
2015-001317-28Phase 2Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of salbutamol in cystic fibrosis (CF), sponsored by University Medical Center Utrecht. Primary endpoint: Pulmonary function change. Started May 2015; status: terminated.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2015-001317-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001317-28.